NL-OMON56864尚未招募不适用
Characterization of aberrant immune response in post-COVID using innovative signal transduction pathway technology (LC-STP) - Immune cell STP*s to characterize Long-COVID
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Long-COVID patients
- •Age >= 18 years, <65 years
- •Past COVID-19 diagnosis, based on
- •o Positive PCR
- •o Positive Sars-Cov2 serology
- •o Positive rapid antigen test
- •o Typical clinical syndrome during the first pandemic wave, when testing was
- •not possible
- •Long-COVID-19 diagnosis based on World Health Organization consensus
- •(*Post COVID-19 condition occurs in individuals with a history of probable or
- •confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19
- •with symptoms and that last for at least 2 months and cannot be explained by an
- •alternative diagnosis. Symptoms may be new onset following initial recovery
- •from an acute COVID-19 episode or persist from the initial illness. Symptoms
- •may also fluctuate or relapse over time)*.
- •https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID19_condition-Cli
- •nical_case_definition-2021.1
- •Overall functioning <70% compared to functioning prior to onset of
- •Long-COVID/ COVID19 infection
- •Presence of post-exertional malaise
- •Provided written informed consent
- •Long COVID symptoms present > 6 months
- •Healthy controls
- •Age >= 18 years, <65 years
- •Past COVID-19 diagnosis, based on
- •o Positive PCR
- •o Positive Sars-Cov2 serology
- •o Positive rapid antigen test
- •o Typical clinical syndrome during the first pandemic wave, when testing was
- •not possible
- •No clinical diagnosis of long-COVID, good recovery. Overall functioning >95%
- •compared to functioning prior COVID-19 infection
- •Self-reported general good wellbeing
- •Provided written informed consent
排除标准
- •Long-COVID patients
- •Unable or not willing to provide written informed consent
- •Unable to complete written questionnaires in Dutch
- •Unable to draw blood for study purposes
- •Diagnosis of dementia
- •Alternative diagnosis that may explain their clinical symptoms
- •Re-infection or booster vaccination with COVID-19 in the past 3 months
- •Suffering from any pre-existing immune-driven disease or use of
- •anti-inflammatory therapy of any kind (including NSAIDs and steroids) during
- •the last 3 months
- •Healthy controls
- •Unable or not willing to provide written informed consent
- •Unable to complete written questionnaires in Dutch
- •Unable to draw blood for study purposes
- •Diagnosis of dementia
- •Genetically related to participating patients (e.g.
- •brother/sister/parent)
- •Suffering from any immune-driven disease or use of anti-inflammatory therapy
- •of any kind
- •(including NSAIDs and steroids), including during the last 3 months
- •Re-infection with SARS-CoV-2 or booster vaccination in the past 3 months.
研究者
相似试验
招募中
不适用
Analysis of the immunological conditions in the intestinal mucosa of inflammatory bowel diseaseJPRN-UMIN000039795Internal Medicine (gastroenterlogy) Tokai University School of Medicine100
尚未招募
2 期
Examinations for immune-biological mechanism of anti-atherosclerotic effects of omega 3 lipid formula, Lotriga, focusing on commensal microbe and serum auto-antibodies.The subjects with hyper-triglyceridemia and atherosclerosis.JPRN-UMIN000032320Yokohama City University Graduate School of Medicine, Department of Medical Science and Cardio-Renal Medicine36
已完成
不适用
Pneumococcal conjugate vaccine trial: PNEUVAC TRIAISRCTN54494731niversity of Liverpool (UK)320
已完成
不适用
Characterization of the immune response in patients with urothelial cell carcinoma of the bladder and during the BCG immunotherapy of bladder cancerC67Malignant neoplasm of bladderDRKS00003700Chirurgische Universitätsklinik, Abteilung für Urologie410
已完成
不适用
In vitro characterization of the immune response of recovered COVID-19 patients and healthy controls to SARS-CoV-2.CoronaCOVID-19SARS-CoV-210047438NL-OMON50131ISA Pharmaceuticals B.V.14